Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid's new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Remember when the COVID vaccine came out and all the "nationalize healthcare" mfs started worshipping pharmaceutical companies as the greatest thing in history? Pretty funny, huh?
Magnificent! You've successfully constructed and attacked a straw-man by conflating economics with medical science, and displayed your total ignorance of ... everything ... in the process...
Remember when the COVID vaccine came out and all the "don't nationalize healthcare" mfs started making up strawmen to argue against because they have no idea what other people actually want for society? Pretty funny, huh?
Here ya go. My point being is that two years ago if you criticized pharmaceutical companies as still being greedy, soulless corporations you'd be laughed at and shadow banned for daring to insult our world's saviors.
I can't decide if using a picture of a tattoo on Reddit as a 'source' is better or worse than a YouTube video with a crazy, ranting flat earther, which is what I see most often.
You weren't the person who said they didn't pay in response to a comment about government paying so I have no idea what the point of your comment is other than "I am smart and I want to passively put you down."
I'm guessing you're an antivaxxer? Everyone still recognized the bs Pfizer and Moderna did during the pandemic. The world is not black and white, bad companies can still do things that benefit society.
What a clown comment. Other countries with universal healthcare pay significantly less for care and pharmaceuticals than Americans because their governments handle the negotiations.
What a clown comment. Other countries with universal healthcare pay significantly less for care and pharmaceuticals because their governments handle the negotiations.